Skip to content

Psychedelic-assisted therapy: all studies

Page 234 of 294: studies 2,331 to 2,340 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review.

Therapeutic Advances in Psychopharmacology 2023 Vivian W. L. Tsang, Brendan Tao, Shannon Dames et al. 19 citations

In the last few years, ketamine is becoming increasingly common in the treatment of mental health conditions, but there is a lack of safety data informing intramuscular and sublingual dosing in a community-focused group psychotherapy setting. The Roots To Thrive ketamine-assisted therapy (RTT-KaT) program is a unique 12-week RTT-KaT program with 12 community of practice (a form of group...

Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics.

Journal of Psychoactive Drugs 2023 Daniel J. Kruger, Julie Barron, Moss Herberholz et al. 4 citations

Legal, scientific, and social landscapes for psychedelics are changing rapidly. Differences of opinion exist among key stakeholders regarding regulatory control, models of provisioning psychedelic therapy, and medicalization, decriminalization, and/or legalization policies. We assessed the policy preferences of people using psychedelics naturalistically (N = 1221) to understand how they aligned...

DOI: 10.1080/02791072.2023.2228784 (opens in new tab) Full text (opens in new tab) Psychedelics Community-based research Policy Preferences

Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.

Missouri medicine 2023 Joshua S. Siegel, Craig S Pearson, Eric J Lenze 592 citations

The 21st century has brought novel therapies and new therapeutic targets for major depressive disorder (MDD). Until recently all antidepressant medications targeted monoamines-serotonin, norepinephrine, and dopamine- and their regulatory systems. But growing evidence has suggested that individuals who fail to respond to a monoaminergic treatment are likely to fail to respond to other...

[Interest and mechanisms of action of ketamine in alcohol addiction- A review of clinical and preclinical studies].

Biologie aujourd'hui 2023 Fahd Hilal, Jérôme Jeanblanc, Mickaël Naassïla 3 citations

Alcohol Use Disorder (AUD) is a psychiatric condition characterized by chronic and excessive drinking despite negative consequences on overall health and social or occupational functioning. There are currently limited treatment options available for AUD, and the effects size and the response rates to these treatments are often low to moderate. The World Health Organization has identified the...

Women and MDMA: particularities of gender and sex.

International Review of Psychiatry 2023 Fabio Carezzato, Ilana Falcão de Arruda, Caio Petrus Monteiro Figueiredo et al. 4 citations

This comprehensive review delves into the intricate interplay between gender/sex and MDMA use, drawing upon recent evidence. It explores how girls, as a means of coping with negative emotions, often resort to drug use, while boys primarily initiate drug use due to peer pressure or sensation-seeking tendencies. Women, frequently having endured traumatic life events, may turn to MDMA as a form of...

History repeating: guidelines to address common problems in psychedelic science

Therapeutic Advances in Psychopharmacology 2023 Michiel van Elk, Eiko I. Fried 126 citations

Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in an increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that threaten the...

The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.

American Journal of Geriatric Psychiatry 2023 C Bree Johnston, Maria Mangini, Charles S. Grob et al. 33 citations

Psychedelics and related compounds have shown efficacy for the treatment of a variety of conditions that are prevalent among older adults, including mood disorders, the psychological distress associated with a serious medical illness, post-traumatic stress disorder (PTSD), and prolonged grief disorder. Psychedelics also have properties that could help provide therapeutic benefits for patients...

DOI: 10.1016/j.jagp.2022.08.007 (opens in new tab) Full text (opens in new tab) Psilocybin 3,4-Methylenedioxymethamphetamine MDMA Pharmacology Psychedelics hallucinogens +5

Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.

Journal of Psychopharmacology 2023 Brent M Kious, Zach Schwartz, Benjamin R. Lewis 44 citations

Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers and lingering questions about study design, such as the difficulty of ensuring adequate blinding, the relative overrepresentation in studies of participants who have previously used psychedelics, and the importance of personal experience with psychedelics for those who provide psychedelic-assisted therapy....

The future of hallucination research: Can hallucinogens and psychedelic drugs teach us anything?

Psychiatry Research 2023 Flavie Waters 1 citation

Hallucinations are one of the most interesting and least understood of all human experiences. This commentary addresses the ideas which most influenced my thinking in the past 20 years and what I believe to be the most currently promising area of enquiry. Interest in hallucinations reaches far back into antiquity and across cultures. The similarity of hallucinations in mental illness with the...

Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment

Perspectives in biology and medicine 2023 Gail A. Edelsohn, Dominic Sisti 8 citations

Recent clinical trials of psychedelic drugs aim to treat a range of psychiatric conditions in adults. MDMA and psilocybin administered with psychotherapy have received FDA designation as "breakthrough therapies" for post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) respectively. Given the potential benefit for minors burdened with many of the same disorders, calls...

DOI: 10.1353/pbm.2023.0007 (opens in new tab) Psilocybin Prologue Psychotherapist Informed consent +1